伊诺图祖马布奥佐加米辛:第一个儿科批准
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. pdd@adis.com.
Paediatric drugs
|May 23, 2024
概括
现在已经批准用于1岁及以上的儿科患者,患有复发或耐药的CD22阳性B细胞前体急性淋巴细胞白血病 (ALL). 这标志着治疗这种侵袭性儿童癌症的重要里程碑.
科学领域:
- 在瘤学瘤学.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 伊诺图祖马布臭胺 (BESPONSATM) 是一种针对CD22的抗体药物联合体 (ADC).
- 它旨在治疗CD22阳性B细胞前体急性淋巴细胞白血病 (ALL).
研究的目的:
- 总结一下inotuzumab ozogamicin 的发展里程碑.
- 为了突出其最近对ALL治疗的儿科批准.
主要方法:
- 开发一种与N-乙--基胺二甲基化物 (CalichDMH) 相关的人性化IgG4抗CD22单克隆抗体.
- 机制涉及针对性地将细胞毒剂输送到表达CD22的瘤细胞,诱导DNA断裂和亡.
主要成果:
- 在全球范围内,伊诺图祖马布 (inotuzumab ozogamicin) 已被批准用于全球成年人复发性/耐药性CD22阳性B细胞前体ALL.
- 在美国获得首次儿科批准 (2024年3月) 用于≥1岁的患者.
- 在日本批准 (2024年3月) 用于相同的儿科适应症.
结论:
- 伊诺图祖马布 (inotuzumab ozogamicin) 为患有复发性或耐火性CD22阳性B细胞前体ALL的儿科患者提供了一个新的治疗选择.
- 该药物的发展里程碑导致了关键的儿科批准,扩大了治疗的可访问性.
相关概念视频
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:29Drug Dosing: Infants and Children
Pediatric patient dosages diverge from adults due to disparities in body surface area, total body water, and extracellular fluid per kilogram of body weight. The dosing regimen considers the variations in pharmacokinetics and pharmacology across distinct age groups, encompassing preterm newborns, infants, young children, older children, and adolescents. Calculation of pediatric patient doses is predicated on determining body surface area, which exhibits a superior correlation with the child's...
01:23Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption
Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
01:17Pharmacokinetics in Pediatric Patients: Drug Distribution
Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight, compared...
01:24Pharmacokinetics in Pediatric Patients: Drug Metabolism
In pediatric care, understanding the nuances of hepatic drug metabolism is crucial, as it significantly differs from that of adults. This divergence is primarily due to the developmental stage of drug-metabolizing enzymes, which affects how medications are processed in the body. In neonates, for instance, the activity of Phase I enzymes—critical for the initial breakdown of drugs—is markedly reduced, functioning at just 20–40% of the levels seen in adults. This reduction poses a challenge in...
01:26Pharmacokinetics in Pediatric Patients: Drug Excretion
In pediatric medicine, understanding the renal function and drug elimination nuances is crucial for administering safe and effective treatments. Newborns, in particular, display markedly slower renal functions than adults, profoundly affecting how drugs are cleared from their bodies. This slower drug clearance requires clinicians to extend the dosing intervals for many medications to prevent drug accumulation and toxicity while ensuring therapeutic efficacy.One key area where these adjustments...